Clinical Trials Browser

Phase 1/2 × Lomustine × 30 days × Clear all

NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Phase 1/2 Terminated

Glioblastoma, Neoplasms